Abstract:Abstract MicroRNAs (miRNAs) are a class of small noncoding RNA molecules containing only 20–22 nucleotides. MiRNAs play a role in gene silencing and translation suppression by targeting and binding to mRNA. Proper control of miRNA expression is very important for maintaining a normal physiological environment because miRNAs can affect most cellular pathways, including cell cycle checkpoint, cell proliferation, and apoptosis pathways, and have a wide range of target genes. With these properties, miRNAs can modulate multiple signalling pathways involved in cancer development, such as cell proliferation, apoptosis, and migration pathways. MiRNAs that activate or inhibit the molecular pathway related to tumour angiogenesis are common topics of research. Angiogenesis promotes tumorigenesis and metastasis by providing oxygen and diffusible nutrients and releasing proangiogenic factors and is one of the hallmarks of tumour progression. CRC is one of the most common tumours, and metastasis has always been a difficult issue in its treatment. Although comprehensive treatments, such as surgery, radiotherapy, chemotherapy, and targeted therapy, have prolonged the survival of CRC patients, the overall response is not optimistic. Therefore, there is an urgent need to find new therapeutic targets to improve CRC treatment. In a series of recent reports, miRNAs have been shown to bidirectionally regulate angiogenesis in colorectal cancer. Many miRNAs can directly act on VEGF or inhibit angiogenesis through other pathways (HIF-1a, PI3K/AKT, etc.), while some miRNAs, specifically many exosomal miRNAs, are capable of promoting CRC angiogenesis. Understanding the mechanism of action of miRNAs in angiogenesis is of great significance for finding new targets for the treatment of tumour angiogenesis. Deciphering the exact role of specific miRNAs in angiogenesis is a challenge due to the high complexity of their actions. Here, we describe the latest advances in the understanding of miRNAs and their corresponding targets that play a role in CRC angiogenesis and discuss possible miRNA-based therapeutic strategies.

Anti‐angiogenesis in colorectal cancer therapy

Anti-angiogenic therapy for colorectal cancer: on the way to getting better!

MicroRNAs and angiogenesis: a new era for the management of colorectal cancer

Advances In Combination Of Antiangiogenic Agents Targeting Vegf-Binding And Conventional Chemotherapy And Radiation For Cancer Treatment

Chronic Inflammation and Colorectal Cancer: the Role of Vascular Endothelial Growth Factor

Blood Vessel-Targeted Therapy in Colorectal Cancer: Current Strategies and Future Perspectives

Angiogenesis-Related Functions of Wnt Signaling in Colorectal Carcinogenesis

Angiogenic signaling pathways and anti-angiogenic therapy for cancer

The Effect of Anti-Vegf Drugs (bevacizumab and Aflibercept) on the Survival of Patients with Metastatic Colorectal Cancer (Mcrc)

Recent advances in, and challenges of, anti-angiogenesis agents for tumor chemotherapy based on vascular normalization

Drug Resistance and New Therapies in Colorectal Cancer

Drug Resistance in Colorectal Cancer: From Mechanism to Clinic

Anti-vascular endothelial growth factor therapy in breast cancer: Molecular pathway, potential targets, and current treatment strategies

Nano-enabled colorectal cancer therapy

The Research Progress of Antiangiogenic Therapy, Immune Therapy and Tumor Microenvironment

Progress on angiogenic and antiangiogenic agents in the tumor microenvironment

MicroRNAs As Regulators, Biomarkers and Therapeutic Targets in the Drug Resistance of Colorectal Cancer

Monotherapy and Combination Therapy Using Anti‐Angiogenic Nanoagents to Fight Cancer

MicroRNA-181a promotes angiogenesis in colorectal cancer by targeting SRCIN1 to promote the SRC/VEGF signaling pathway

Research progress in tumor angiogenesis and drug resistance in breast cancer